利妥昔单抗治疗 IgA 血管炎肾炎的疗效。
The efficacy of rituximab in the treatment of IgA vasculitis nephritis.
机构信息
The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, Jiangxi, People's Republic of China.
Molecular Inflammation Group, Biomedical Research Institute of Murcia, University Clinical Hospital Virgen de Arrixaca, Murcia, Spain.
出版信息
Clin Exp Med. 2024 Sep 9;24(1):213. doi: 10.1007/s10238-024-01461-6.
The utility of Rituximab (RTX) for IgA vasculitis nephritis (IgAVN) is not well established. Up to now, we analysed the largest samples of IgAVN patients treated by RTX with a total of 41 retrieved subjects up to December 29, 2023 in the present systematic review. We assessed the clinical profiles, efficacy, and safety of RTX treatments. The present review showed that the renal function tended to be stabilized (P = 1.000) and urinalysis tended to normalize after RTX treatment with no serious adverse events reported. Moreover, 40% (16/40) of patients was freed use of glucocorticoid after RTX administration (P < 0.001). The remission rate was 92.7% (38/41) and complete remission rate was 46.3% (19/41) in IgAVN patients. Interestingly, 76.9% (10/13) of IgAVN child patients achieved complete remission when compared with 32.1% (9/28) of adult patients (P = 0.017). In summary, our results support the benefit of RTX therapy in IgAVN patients, especially children subjects.
利妥昔单抗（RTX）在 IgA 血管炎肾炎（IgAVN）中的应用尚未得到充分证实。截至目前，我们通过系统评价分析了迄今为止最大的一组接受 RTX 治疗的 IgAVN 患者样本，共纳入 41 例患者，数据截至 2023 年 12 月 29 日。我们评估了 RTX 治疗的临床特征、疗效和安全性。本研究表明，RTX 治疗后肾功能趋于稳定（P=1.000），尿液分析趋于正常，且无严重不良事件报告。此外，40%（16/40）的患者在接受 RTX 治疗后停用了糖皮质激素（P<0.001）。IgAVN 患者的缓解率为 92.7%（38/41），完全缓解率为 46.3%（19/41）。有趣的是，与成年患者（32.1%，9/28）相比，IgAVN 儿童患者的完全缓解率为 76.9%（10/13）（P=0.017）。综上所述，我们的研究结果支持 RTX 治疗 IgAVN 患者，尤其是儿童患者的有效性。
Zotero 插件